Retreatment with Hyaluronic Acid Viscosupplementation in Knee Osteoarthritis: Agreement between EUROVISCO Guidelines and Current Medical Practice

Introduction

Viscosupplementation (VS) by intra-articular injection of hyaluronic acid (HA) is commonly used in the treatment of osteoarthritis (OA). This therapeutic modality is recommended by many scientific societies in patients with knee OA where pain is not adequately relieved with conventional therapy.^1-3 The success rate of VS increases when the indication is correctly set and the injection is correctly performed. ⁴ With the aim of increasing this success rate, the European Viscosupplementation Consensus Group (EUROVISCO) expert group has published recommendations to help practitioners using VS.^5-7 In September 2016, the EUROVISCO working group drew up a set of suggestions to help practitioners in the decision of retreatment with VS in patients with knee OA who have been previously treated with VS injections. ⁷ The task force built two separate decision algorithms based on the clinical result of the previous treatment. They have considered two scenarios: (1) the reinjection in patients successfully treated with VS, 6-12 months ago and (2) the reinjection in patients where previous VS failed or caused adverse reactions. The purpose of that recommendation was to consider all the factors that can influence, positively or negatively, a doctor’s decision to retreat patients with VS and also to build a decision-supporting algorithm. ⁴ In patients not satisfied with previous VS, several predictors of treatment failure have been identified. The unanimously identified factors were a wrong clinical analysis of pain, the extra-articular delivery of the HA, obesity, patellofemoral OA (isolated or severe), and very severe tibio-femoral joint space narrowing. Before taking the decision to retreat with VS in patients where VS failed, the first step in the decision tree was to confirm the appropriate indication. If indication was incorrect, one should not repeat VS injection and instead change to a more appropriate treatment by choosing one more adapted to the clinical situation. If the indication was correct but with concomitant one or several predictive factors of failure, the working group recommended to discuss other treatment options with the patient after explaining that the chances of success of a new or repeat VS are low. Another very frequent clinical scenario addressed by the EUROVISCO group was a patient, who significantly improved with VS, and returned to follow-up, 6-12 months later. Four different case scenarios were identified: (1) the patient remains “symptom free,” (2) the patient remains “minimally symptomatic” but with no increasing pain, (3) the patient is “minimally symptomatic” but with increasing pain, or (4) the patient is symptomatic again. In the first situation, the EUROVISCO working group did not recommend to retreat systematically. Consequently, it advised retreatment as soon as the pain recurs and if pain exceeds the Patient Acceptable Symptom State (PASS) threshold. In “minimally symptomatic” patients with no increase of pain, the EUROVISCO group proposed to retreat young patients, early stages of OA, patients with risk factors of progression, professional sportsmen, and patients with severe comorbidities. Those patients at high risk of disease progression could be retreated 12 months after the first injection even if they are asymptomatic.

The goal of this survey was to assess whether the current clinical practice followed the recommendations of the EUROVISCO in terms of retreatment with VS in patients suffering from knee OA. This study followed three objectives: The primary objective was to measure the agreement rate of the current clinical practice with the EUROVISCO decision algorithms for the retreatment with VS in patients suffering from knee OA over a broad range of physicians from several specialization, the secondary objective was to assess whether there were different agreement rates with EUROVISCO algorithm for re-VS between physicians’ specialization, and finally, the exploratory objective was to identify the most common causes of discrepancies in VS decisions.

Materials and Methods

Results

A total of 506 practitioners participated to the exercise, of which 399 gave their decision about the case assigned to them by the platform. Demographic and professional characteristics of participants are presented in Table 1 .

OPEN IN VIEWER

Table 1.

Demographic and Professional Characteristics of the 506 (399) Participants.

Characteristics	Values
Age range, years	%
20-29	4.7 (6.4)
30-39	26.2 (33.3)
40-49	13.6 (18.2)
50-59	14.6 (18.9)
60-69	14 (17.8)
70-79	1.1 (0.1)
90-99	0.1 (0.1)
Unknown	25.2 (5.2)
Specialization	%
Rheumatologist	30.2 (32.3)
Physical therapist	38.5 (40.1)
Orthopedic surgeon	25.3 (22.8)
General practitioner	5.93 (4.76)
Country of activity	%
Belgium	2.37 (3.01)
France	21.3 (27.1)
Germany	14.2 (18.0)
Italy	3.16 (4.01)
Portugal	1.38 (1.75)
Turkey	28.9 (36.6)
Other	3.39 (4.27)
Unknown	25.3 (5.26)
Type of medical activity	%
Hospital	19.4 (24.6)
Mixed practice (private + hospital)	14.6 (18.5)
Private practice (several)	13.4 (17.0)
Private practice (single)	9.49 (12.0)
University hospital	17.8 (22.6)
Unknown	25.3 (5.26)
Knowledge about recommendations	%
Yes	20.9 (26.6)
No	53.8 (68.2)
Unknown	25.3 (5.26)
Years of practice	%
0-4	10.1 (12.8)
5-9	15.4 (19.5)
10-14	11.3 (14.3)
15-19	4.94 (6.27)
20-24	9.68 (12.3)
25-29	7.91 (10.0)
>30	13.0 (16.5)
Unknown	27.7 (8.27)
Frequency of viscosupplementation injection	%
Never	0.99 (1.25)
<1×/year	1.78 (2.26)
1×/year	5.93 (7.52)
1×/month	16.4 (20.8)
1×/week	15.6 (19.8)
>1×/week	34.0 (43.1)
Unknown	25.3 (5.26)

Among them, 235 (59%) agreed with the EUROVISCO recommendations and 164 (41%) disagreed ( Fig. 1 ). The probability to be agreed with the recommendations was significant with a value of P < 0.001. Only 16% of physicians were retreating patients who should not have been retreated as recommended. Inversely, 24.5% of the physician did not reinjected patients who should be retreated according to the guidelines.

OPEN IN VIEWER

Figure 1.

The confusion matrix. Columns correspond to the European Viscosupplementation Consensus Group algorithm recommendations. Rows represent individual decisions by the participants. The bottom row corresponds to missing answers.

“Over-treatment” was defined as a decision by the physician to retreat with VS, while EUROVISCO recommendation would be not to retreat. “Under-treatment” was then defined as the decision not to retreat with VS, while EUROVISCO recommendation would be to retreat. Comparing medical disciplines in terms of overtreatment or undertreatment showed that orthopedic surgeons tended to be those that overtreat the most (44%), while rheumatologists were the least overtreating (29%). In-between, physiotherapists overtreated in 40% of the cases. In contrast, rheumatologists were those that tended to undertreat their patients the most (53%), while orthopedic surgeons were those who undertreated the less (31%). In-between, physiotherapists undertreated in 42% of the cases. Despite this, no significant difference between specialization was observed.

No significant difference between countries was observed in terms of agreement with the recommendation. Belgian, French, and Italian physicians tended to under retreat patients comparing with other countries, but the difference between countries was not significant (Belgium 70%, France 58%, Italy 57%, Turkey 42%, and Germany 28%). Of note, there was an important correlation between the country of each participant and the distribution of the discipline. It might thus be possible that different terms cover overlapping realities in practice, just named differently depending on the country.

Further, no clear difference was observed between doctors practicing in private or in the hospital in terms of agreement to retreat. There was no difference between physicians working at university hospitals and those working in nonuniversity hospitals.

There was also no significant difference between physicians that knew the EUROVISCO recommendations and those that did not know these recommendations.

The age of the physician and the number of years of practice were not factors that influence decision to retreat with VS.

When the number of questions asked by the doctor about the story (n of clicks) was higher, a tendency for less overtreatment, but no strong tendency about undertreatment, was observed.

After corrections, the five questions the most asked by the physicians were (1) does the patient have previous injection of corticosteroids? (2) according the patient, what is the efficacy level of the treatment after 6 months? (3) does the patient wish to be or not retreated? (4) does patient have current consumption of nonsteroidal anti-inflammatory drugs (NSAIDs)? and finally, (5) is there another cause of knee pain than OA (e.g. meniscal tear, trauma, tendinitis, and osteonecrosis)?

Discussion

In general, evidence-based recommendations are established on the basis of a systematic review of the literature and/or meta-analyses and the opinion of expert researchers or clinicians. Too often, these recommendations are the object of criticism because they are too far removed from medical practice. It is for this reason that the EUROVISCO group investigated whether its recommendations were in line with medical practice. To this end, we asked European physicians to choose whether or not to retreat fictitious cases of patients suffering from OA of the knee and to compare their choice with that of the decision-making algorithm established by the EUROVISCO experts group. This approach was original and according to our knowledge had never been carried out in the field of OA.

By this way, we have demonstrated that a majority of physicians followed in their practice the EUROVISCO recommendations. However, 25% did not reinjected patient, while EUROVISCO group was recommended to do that. We can make several hypotheses to explain this difference: (1) ignorance of the EUROVISCO recommendations. Indeed, only 28% of the participants said they knew about these recommendations. Those who knew the guidelines tended to retreat more frequently that those who did not know the EUROVISCO guidelines; (2) the definition of treatment failure was often subjective in the current medical practice, while EUROVISCO algorithm impose objective criteria. To define the failure of treatment, the EUROVISCO group used the PASS defined as the value beyond which patients consider themselves well (i.e., strictly < at 4 on a 10-point rating scale); (3) in real life, recurrence or increase in pain if often the criteria used to decide for a reinjection while the EUROVISCO algorithm also consider retreatment in asymptomatic or minimally symptomatic patients with early stage of OA, young age, risks factors of progression, and professional sportsperson. Severe comorbidities that contraindicate NSAIDs and surgery were also considered as arguments in favor of an earlier retreatment.

This study also showed that only two thirds of the participants followed recommendations in terms of retreatment. This point could be taken into consideration in the interpretation of real-life postmarketing clinical trials and could affect the long-term potential chondroprotective effects of VS. Indeed, as mentioned before, 25% of the physicians did not retreated while they should retreated if they followed the recommendation limiting the potential beneficial effect of multiple injection on cartilage metabolism.

The more the doctor asked questions about the fictitious case, the less they tended to retreat patients with VS. One explanation is that a high number of questions allow them to identify risk factors of VS failure. The five most often questions were (1) does the patient have previous injection of corticosteroids? (2) according the patient, what is the efficacy level of the treatment after 6 months? (3) does the patient wish to be or not retreated? 4) does the patient have current consumption of NSAIDs? and finally, (5) is there another cause of knee pain than OA (e.g. meniscal tear, trauma, tendinitis, and osteonecrosis)? Interestingly, these questions allowed the physician to identify criteria that were included in the EUROVISCO algorithm. In contrast, the less selected questions were those related to confounding factors (i.e. Does patient have vascular pathology in lower limb? Does patient have edema in lower limb?). This confirms that criteria used in the EUROVISCO are in line with the current clinical practice.

Another important observation of this study is that the type of practice (private or hospital), specialization, number of years of practice, age, or even geographical location did not significantly influence the decision to retreat with VS. This suggests that the decision to retreat is influenced more by medical criteria than by socioeconomic considerations. However, these exploratory data have to be interpreted with caution since the sample size was too small. Indeed, having 200 physicians per specialization, that is, 800 physicians in total, was required to show significant results for differences in agreement rates of at least 15%.

This work has some other limitations. A written survey always exposes to the risk of looking for the “best” response and might artificially increase the gap between written answers and the real life. The survey was conducted in different countries with several differences in terms of patients’ profile and social insurance. Furthermore, the recruitment was not homogenous and some countries (France and Turkey) recruited far more than others and this may influence the final results.

Conclusions

The EUROVISCO recommendations for VS retreatment for knee OA and clinical practice significantly agree in a majority of cases. EUROVISCO recommendations consider decision criteria that are clearly matching those of practitioners in real life. These include patients’ willingness to be treated or patients’ perception about treatment efficacy.

Supplemental Material

Supplemental Material